| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012 | 1320 | 2012 |
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012 | 1305 | 2012 |
| Gender differences in autoimmune disease ST Ngo, FJ Steyn, PA McCombe Frontiers in neuroendocrinology 35 (3), 347-369, 2014 | 1185 | 2014 |
| Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases PA Mcombe, JD Pollard, JG McLeod Brain 110 (6), 1617-1630, 1987 | 575 | 1987 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 551 | 2019 |
| Effects of gender in amyotrophic lateral sclerosis PA McCombe, RD Henderson Gender medicine 7 (6), 557-570, 2010 | 463 | 2010 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 460 | 2016 |
| Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology W Van Rheenen, RAA Van Der Spek, MK Bakker, JJFA Van Vugt, PJ Hop, ... Nature genetics 53 (12), 1636-1648, 2021 | 397 | 2021 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 293 | 2017 |
| Apoptosis in the nervous system in experimental allergic encephalomyelitis MP Pender, KB Nguyen, PA McCombe, JFR Kerr Journal of the neurological sciences 104 (1), 81-87, 1991 | 276 | 1991 |
| The role of immune and inflammatory mechanisms in ALS P A McCombe, R D Henderson Current molecular medicine 11 (3), 246-254, 2011 | 263 | 2011 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 248 | 2017 |
| Hypermetabolism in ALS is associated with greater functional decline and shorter survival FJ Steyn, ZA Ioannides, RPA Van Eijk, S Heggie, KA Thorpe, A Ceslis, ... Journal of Neurology, Neurosurgery & Psychiatry 89 (10), 1016-1023, 2018 | 239 | 2018 |
| Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms JM Greer, PA McCombe Journal of neuroimmunology 234 (1-2), 7-18, 2011 | 222 | 2011 |
| Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ... Annals of neurology 80 (1), 89-100, 2016 | 220 | 2016 |
| Sexual dimorphism in autoimmune disease PA McCombe, JM Greer, IR Mackay Current molecular medicine 9 (9), 1058-1079, 2009 | 214 | 2009 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 195 | 2015 |
| The effect of ageing on human lymphocyte subsets: comparison of males and females J Yan, JM Greer, R Hull, JD O'Sullivan, RD Henderson, SJ Read, ... Immunity & Ageing 7, 1-10, 2010 | 188 | 2010 |
| Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 179 | 2017 |
| The peripheral neuropathy of vitamin B12 deficiency PA McCombe, JG McLeod Journal of the neurological sciences 66 (1), 117-126, 1984 | 152 | 1984 |
Robert David HendersonUniversity of Queensland在 health.qld.gov.au 的电子邮件经过验证